finanzwire.de

Search

MOLOGEN AG (FRA:MGN) DGAP-News: MOLOGEN to present poster at European Cancer Congress 2015 (news with additional features)

Transparency directive : regulatory news

24/09/2015 09:10

08/10/2018 17:29
04/10/2018 11:08
27/09/2018 07:36
26/09/2018 16:52
03/09/2018 08:46
03/09/2018 07:55
01/09/2018 19:29
15/08/2018 21:40
09/08/2018 07:15
01/08/2018 10:10
DGAP-News: MOLOGEN AG / Key word(s): Conference MOLOGEN to present poster at European Cancer Congress 2015 (news with additional features) 24.09.2015 / 09:10 --------------------------------------------------------------------- PRESS RELEASE N 16 / 2015 of 09/24/2015 MOLOGEN to present poster at European Cancer Congress 2015 Berlin, September 24, 2015 - The biotechnology company MOLOGEN AG will present a poster on the immunotherapy MGN1703 at the European Cancer Congress (ECC 2015) in Vienna (September 25 - 29, 2015). The poster is featuring data from the phase II IMPACT trial in colorectal cancer patients. Furthermore, in the framework of the conference, an investigator meeting is scheduled for the randomized lung cancer study IMPULSE. Abstract details: Abstract number: 2089 (used in the programme and online abstract book) Title: "Response to chemotherapy allows to identify mCRC patients most likely to benefit from maintenance immunotherapy: A post-hoc analysis from the IMPACT study" Poster presentation: "Gastrointestinal Malignancies - Colorectal Cancer" on September 27, 2015 from 9:15 a.m. to 11:15 a.m. in Hall C. For more information on the ECC 2015 please visit the website www.europeancancercongress.org . MOLOGEN AG With new and unique technologies and active substances, the biotech company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases. The cancer immunotherapy MGN1703 is the company's lead product and best-in-class TLR9 agonist. Treatment with MGN1703 triggers a broad and strong activation of the immune system. Due to this mechanism of action, MGN1703 has the potential to be applied to various indications. MGN1703 is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore it is also being investigated in a phase I study in HIV. MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a high medical need. MOLOGEN AG is listed on the stock exchange and its headquarters are located in Berlin, Germany. The shares of the company are listed on the Prime Standard at the Frankfurt Stock Exchange (ISIN DE0006637200). www.mologen.com Memberships in associations: Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI) MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Claudia Nickolaus Head of Investor Relations & Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation. +++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=IWIFPCXMRE Document title: MOLOGEN to present poster at European Cancer Congress 2015 --------------------------------------------------------------------- 24.09.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: MOLOGEN AG Fabeckstraße 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: presse@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------- 397117 24.09.2015